Clinical Trial Update: A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating Vepugratinib (LY3866288) in participants with urinary tract cancers, including transitional cell carcinoma and bladder cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Transitional Cell Carcinoma
• Urinary Bladder Cancer

Drugs mentioned

• Vepugratinib (LY3866288) (Vepugratinib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Carcinoma, Transitional Cell, Urinary Bladder Neoplasms | Phase 3 | Status: RECRUITING